Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has appointed Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the senior executive team. Dr. Ronsheim, with 25 years of experience in pharmaceutical development and manufacturing, will lead Chemistry, Manufacturing and Controls (CMC), Program Management, and Quality Assurance. He will focus on preparing for the commercial launch of azetukalner, Xenon's lead Kv7 channel opener in late-stage clinical development for epilepsy and depression.
Dr. Ronsheim joins Xenon from Innoviva Specialty Therapeutics, where he served as President. His extensive experience includes leadership roles at Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. His appointment comes at a important time as Xenon advances its Phase 3 epilepsy and MDD programs and progresses its pre-clinical assets.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) ha nominato Matthew D. Ronsheim, Ph.D. come Chief Operating Officer e membro del team esecutivo senior. Il Dr. Ronsheim, con 25 anni di esperienza nello sviluppo e nella produzione farmaceutica, guiderà il Chemistry, Manufacturing and Controls (CMC), la gestione dei programmi e l'assicurazione della qualità. Si concentrerà sulla preparazione per il lancio commerciale di azetukalner, il principale apritore del canale Kv7 di Xenon attualmente in fase clinica avanzata per l'epilessia e la depressione.
Il Dr. Ronsheim si unisce a Xenon da Innoviva Specialty Therapeutics, dove ha ricoperto il ruolo di Presidente. La sua vasta esperienza include ruoli dirigenziali in Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals e Forest Laboratories. La sua nomina avviene in un momento importante, poiché Xenon sta avanzando nei suoi programmi di fase 3 per l'epilessia e la depressione maggiore e sta sviluppando i suoi asset preclinici.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) ha nombrado a Matthew D. Ronsheim, Ph.D. como Director de Operaciones y miembro del equipo ejecutivo senior. El Dr. Ronsheim, con 25 años de experiencia en el desarrollo y la fabricación farmacéutica, liderará Química, Fabricación y Control (CMC), Gestión de Programas y Aseguramiento de Calidad. Se centrará en la preparación para el lanzamiento comercial de azetukalner, el principal abridor del canal Kv7 de Xenon que se encuentra en desarrollo clínico avanzado para la epilepsia y la depresión.
El Dr. Ronsheim se une a Xenon desde Innoviva Specialty Therapeutics, donde ocupó el cargo de Presidente. Su amplia experiencia incluye roles de liderazgo en Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals y Forest Laboratories. Su nombramiento llega en un momento importante, ya que Xenon avanza en sus programas de fase 3 para la epilepsia y el trastorno depresivo mayor, y progresa en sus activos preclínicos.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE)는 Matthew D. Ronsheim, Ph.D.를 최고 운영 담당자(COO)이며 고위 경영진의 일원으로 임명했습니다. Ronsheim 박사는 제약 개발 및 제조 분야에서 25년의 경험을 가지고 있으며, 화학, 제조 및 품질 관리(CMC), 프로그램 관리, 품질 보증을 담당하게 됩니다. 그는 azetukalner의 상업적 출시 준비에 집중할 예정이며, 이는 발작과 우울증 치료를 위한 Xenon의 주요 Kv7 채널 개방제입니다.
Ronsheim 박사는 Innoviva Specialty Therapeutics에서 사장직을 역임한 후 Xenon에 합류했습니다. 그의 폭넓은 경험에는 Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals 및 Forest Laboratories에서의 리더십 역할이 포함됩니다. 그의 임명은 Xenon이 3상 취급 및 주요 우울 장애 프로그램을 발전시키고 있고, 사전 임상 자산을 개발하며 중요한 시기에 이루어졌습니다.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) a nommé Matthew D. Ronsheim, Ph.D. en tant que directeur des opérations et membre de l'équipe de direction. Le Dr Ronsheim, fort de 25 ans d'expérience dans le développement et la fabrication pharmaceutique, dirigera la chimie, la fabrication et les contrôles (CMC), la gestion de programme et l'assurance qualité. Il se concentrera sur la préparation du lancement commercial de azetukalner, le principal activateur du canal Kv7 de Xenon en phase avancée de développement clinique pour l'épilepsie et la dépression.
Le Dr Ronsheim rejoint Xenon en provenance d'Innoviva Specialty Therapeutics, où il était président. Son expérience extensive comprend des rôles de leadership chez Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals et Forest Laboratories. Sa nomination intervient à un moment crucial alors que Xenon fait progresser ses programmes de phase 3 pour l'épilepsie et le trouble dépressif majeur (MDD) tout en développant ses actifs précliniques.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) hat Matthew D. Ronsheim, Ph.D. zum Chief Operating Officer und Mitglied des Senior Executive Teams ernannt. Dr. Ronsheim bringt 25 Jahre Erfahrung in der pharmazeutischen Entwicklung und Herstellung mit und wird die Bereiche Chemie, Herstellung und Kontrolle (CMC), Programmmanagement und Qualitätssicherung leiten. Er wird sich auf die Vorbereitung der Markteinführung von azetukalner, Xenons führendem Kv7-Kanalöffner in der späten klinischen Entwicklung für Epilepsie und Depression, konzentrieren.
Dr. Ronsheim kommt von Innoviva Specialty Therapeutics, wo er als Präsident tätig war. Seine umfangreiche Erfahrung umfasst Führungspositionen bei Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals und Forest Laboratories. Seine Ernennung erfolgt zu einem wichtigen Zeitpunkt, da Xenon voranschreitet mit seinen Phase-3-Programmen für Epilepsie und Major Depression Disorder (MDD) und seine präklinischen Vermögenswerte weiterentwickelt.
- Appointment of experienced pharmaceutical executive as COO
- Focus on commercial launch preparation for lead drug candidate azetukalner
- Advancement of Phase 3 epilepsy and MDD programs
- Progress in pre-clinical assets development
- None.
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company’s pipeline of small molecule programs with a focus on preparation for the commercial launch of azetukalner.
“Matt joins Xenon at an exciting time of growth where his extensive operational, pharmaceutical development and manufacturing expertise will help support the advancement of our Phase 3 epilepsy and MDD programs, planning for regulatory submissions and commercialization, while also progressing our broad portfolio of pre-clinical assets that will fuel future growth,” stated Ian Mortimer, President and Chief Executive Officer of Xenon.
Dr. Ronsheim has 25 years of experience bringing important medicines from discovery through clinical development, global regulatory filings and approvals, and commercial launch and supply. Before joining Xenon, Dr. Ronsheim was President of Innoviva Specialty Therapeutics, having previously served as their Chief Technical Officer. Prior to this, Dr. Ronsheim was President of Entasis Therapeutics, which was acquired by Innoviva, Inc. in 2022. Throughout his career, he has held leadership roles overseeing research, CMC, pharmaceutical development, and commercialization at companies including Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. Dr. Ronsheim’s industry contributions and leadership have contributed to delivering important therapies across several disease areas including central nervous system disorders. Dr. Ronsheim holds a B.S. in Chemistry from Southern Connecticut State University and a Ph.D. in Synthetic Organic Chemistry from the University of New Hampshire.
“I am thrilled to join Xenon to support the future development and commercialization of azetukalner given its compelling profile in both epilepsy and depression with a broad Phase 3 program underway,” said Dr. Matt Ronsheim, Chief Operating Officer of Xenon. “I am also excited about the opportunity to deliver on Xenon’s promise of a next-generation ion channel modulators with the advancement of multiple Kv7, Nav1.7 and Nav1.1 molecules creating opportunities for development across a broad range of CNS indications.”
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
Who is the new Chief Operating Officer of Xenon Pharmaceuticals (XENE)?
What is azetukalner and what is it being developed for by Xenon (XENE)?
What are the main responsibilities of Dr. Ronsheim in his new role at Xenon (XENE)?
What is the current stage of development for Xenon's (XENE) epilepsy and MDD programs?
